Diabetes medication tirzepatide shows promise for treating sleep disorder

Researchers have found tirzepatide, a diabetes medication, to be an effective treatment for Obstructive Sleep Apnea (OSA). The study, published in the New England Journal of Medicine, involved 469 participants with OSA. Tirzepatide led to a significant decrease in breathing interruptions during sleep, improving OSA severity. This breakthrough offers hope for the 936 million OSA patients globally, potentially reducing the need for CPAP therapy.